Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Chalcis – page 7

159 clinical trials in Chalcis, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Chalcis at a glance
159
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

159 trials in Chalcis

Open in trial search

Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dordaviprone
  • Sponsor:Institut Gustave Roussy

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Amgen Inc.

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Diabetic neuropathy+2

Not yet recruiting

Efficacy and Safety of OXT-328 5% Topical Gel for Symptom Relief in Patients with Chemotherapy‑Induced, Diabetic, and Cervical Radiculopathy Peripheral Neuropathy

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:Jcare Pharmaceuticals LLC

Sepsis

Not yet recruiting

Clarithromycin to prevent secondary infections in adult patients with community-acquired pneumonia-related sepsis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Clarithromycin
  • Sponsor:Hellenic Institute For The Study Of Sepsis

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Bacterial infection+1

Not yet recruiting

A study to evaluate the use of meropenem to reduce the risk of sepsis in patients with suspected infection in the emergency department

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Meropenem Anhydrous
  • Sponsor:Hellenic Institute For The Study Of Sepsis

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Chalcis

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Chalkida is focused entirely on cardiovascular diseases, with studies centered on different forms of heart failure. The research is mainly aimed at evaluating new treatment approaches that may help reduce serious heart-related events and improve symptom control.

  • Heart failure with reduced ejection fraction
  • HFpEF and HFmrEF linked to obesity
  • Heart failure with systemic inflammation
  • Testing whether new therapies can improve outcomes beyond standard care

These trials are exploring both treatment effectiveness and the potential to lower risks such as cardiovascular death, hospitalisation, and urgent care visits.

02 Heart Failure Research

Current studies in this area are examining whether targeted therapies can better manage symptomatic heart failure in patients whose condition remains difficult to control. The focus is on improving long-term outcomes for people with more advanced forms of the disease.

  • HFrEF with severely reduced ejection fraction
  • Comparing a new treatment with placebo
  • Assessing added benefit alongside guideline-directed medical therapy

This line of research aims to clarify whether new options can offer meaningful benefit in everyday clinical care.

03 Inflammation and Obesity in Heart Failure

Another important research theme links heart failure with systemic inflammation and obesity, reflecting growing interest in how these factors influence disease progression. The studies are designed to test whether newer therapies can address these overlapping risks more effectively.

  • HFpEF and HFmrEF with obesity
  • Heart failure with inflammation
  • Evaluating whether treatment can reduce major cardiovascular events
  • Supporting better control of complex, mixed-risk patient groups

Together, these trials reflect a focused effort in Greece to improve care for people living with challenging forms of heart failure.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.